About: Intravitreal Bevacizumab With or Without Triamcinolone for Refractory Diabetic Macular...

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Intravitreal Bevacizumab With or Without Triamcinolone for Refractory Diabetic Macular... Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	We evaluate the effect of intravitreal injections of Bevacizumab (IVB) alone or combined with triamcinolone (IVT) in the first injection for treatment of refractor), diabetic macular oedema (DME). Sixty eyes of sixty patients with refractory DME were included. Half of the receive injections of IVB (1.25 mg/0.05 mL) or combined IVB and IVT (1.25 mg/0.05 mL and 2 mg/0.05 mL respectively). The primary outcome measure was change in central macular thickness (CMT). Secondary outcome measures were change in best-corrected logMAR visual acuity (BCVA) and incidence of potential adverse events. Central macular thickness was reduced significantly in both the IVB and IVB/IVT groups. At week 24, CMT change compared to the baseline was -95.7 mu m (95% CI, -172.2 to -19.26) in the IVB group and -92.1 mu m (95% CI, -154.4 to -29.7) in the IVB/IVT group. There was not a significant difference between the IVB and the IVB/IVT groups (p=0.022). We evaluate the effect of intravitreal injections of Bevacizumab (IVB) alone or combined with triamcinolone (IVT) in the first injection for treatment of refractor), diabetic macular oedema (DME). Sixty eyes of sixty patients with refractory DME were included. Half of the receive injections of IVB (1.25 mg/0.05 mL) or combined IVB and IVT (1.25 mg/0.05 mL and 2 mg/0.05 mL respectively). The primary outcome measure was change in central macular thickness (CMT). Secondary outcome measures were change in best-corrected logMAR visual acuity (BCVA) and incidence of potential adverse events. Central macular thickness was reduced significantly in both the IVB and IVB/IVT groups. At week 24, CMT change compared to the baseline was -95.7 mu m (95% CI, -172.2 to -19.26) in the IVB group and -92.1 mu m (95% CI, -154.4 to -29.7) in the IVB/IVT group. There was not a significant difference between the IVB and the IVB/IVT groups (p=0.022). (en)
Title	Intravitreal Bevacizumab With or Without Triamcinolone for Refractory Diabetic Macular... Intravitreal Bevacizumab With or Without Triamcinolone for Refractory Diabetic Macular... (en)
skos:prefLabel	Intravitreal Bevacizumab With or Without Triamcinolone for Refractory Diabetic Macular... Intravitreal Bevacizumab With or Without Triamcinolone for Refractory Diabetic Macular... (en)
skos:notation	RIV/00216224:14110/10:00061165!RIV13-MSM-14110___
http://linked.open...avai/riv/aktivita	I
http://linked.open...avai/riv/aktivity	I
http://linked.open...iv/cisloPeriodika	Suppl. 2
http://linked.open...vai/riv/dodaniDat	2013
http://linked.open...aciTvurceVysledku	Synek, Svatopluk
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Masarykova univerzita / Lékařská fakulta
http://linked.open...dnocenehoVysledku	264716
http://linked.open...ai/riv/idVysledku	RIV/00216224:14110/10:00061165
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	bevacizumab; diabetic macular oedema (en)
http://linked.open.../riv/klicoveSlovo	bevacizumab diabetic macular oedema
http://linked.open...odStatuVydavatele	HR - Chorvatská republika
http://linked.open...ontrolniKodProRIV	[FBAEE3241D6D]
http://linked.open...i/riv/nazevZdroje	Collegium Antropologicum
http://linked.open...in/vavai/riv/obor	FP
http://linked.open...ichTvurcuVysledku	1 (xsd:int)
http://linked.open...cetTvurcuVysledku	2 (xsd:int)
http://linked.open...UplatneniVysledku	2010
http://linked.open...v/svazekPeriodika	34
http://linked.open...iv/tvurceVysledku	Synek, Svatopluk Vojnikovic, Bozo
http://linked.open...ain/vavai/riv/wos	000283961100021
issn	0350-6134
number of pages	5 (xsd:int)
http://localhost/t...ganizacniJednotka	14110

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 77 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software